Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Key Oncologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 19, 2020
PharmaMar will retain exclusive production rights for Yondelis®(trabectedin), which will be sold to Key Oncologics for its clinical and commercial use in South Africa, Namibia and Botswana.